FDA Cites Shoolin Pharma Chem LLP in 2026-08-18 Warning Letter — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
TL;DR
Here's the summary: On August 18, 2026, FDA's Center for Drug Evaluation and Research (CDER) issued a Warning Letter (Reference 320-26-116) to Shoolin Pharma Chem LLP, a drug manufacturing facility in Ahmedabad, Gujarat, India (FEI 3038200383), citing significant CGMP violations and insanitary conditions observed during an April 13-17, 2026 inspection. The FDA documented that APIs including sildenafil citrate and tadalafil manufactured at the facility for U.S. compounding pharmacies were adulterated due to layered unidentified residues, corroded equipment, improperly gowned employees, and lack of written cleaning/maintenance procedures, with no cleaning verification testing performed. The FDA required the firm to submit a comprehensive remediation plan, detailed sanitary procedures, and photographic evidence of facility remediation.
Argus analysis
# FDA Warning Letter Analysis: Shoolin Pharma Chem LLP
**Company and Findings**
Shoolin Pharma Chem LLP, an active pharmaceutical ingredient (API) manufacturer based in Gujarat, India, received a Warning Letter from the FDA's Center for Drug Evaluation and Research (CDER) on August 18, 2026, following an inspection conducted April 13–17, 2026. The facility manufactures APIs including sildenafil citrate and tadalafil for U.S. compounding pharmacies. FDA investigators documented pervasive insanitary conditions including layered unidentified residues, improperly gowned employees wearing open-toed sandals in production areas, corroded equipment surfaces near open processing lines, and product transfer lines stored with contamination risk. These conditions rendered drug products adulterated under section 501(a)(2)(A) of the FD&C Act.
**Regulatory Citations**
The violations primarily cited 21 CFR sections addressing equipment cleanliness and control (section 211.63) and laboratory records completeness (section 211.192). Section 501(a)(2)(A) of the FD&C Act addresses preparation under insanitary conditions; section 501(a)(2)(B) addresses failure to conform to CGMP. These citations reflect requirements that manufacturing environments prevent product contamination and that analytical data supporting quality claims be fully documented and traceable to actual testing performed.
**Response Timeline and Monitoring**
The company submitted an initial May 2, 2026 response to FDA Form 483 observations, which FDA deemed inadequate on multiple fronts. Compliance officers in pharmaceutical manufacturing should monitor for submission of a comprehensive remediation plan with photographic evidence, detailed CAPA documentation addressing cross-contamination assessment, and cleaning validation studies with worst-case scenarios. Failure to adequately address violations within a reasonable timeframe may result in regulatory action including import detention or product seizure. Public records and FDA enforcement updates will indicate progress toward compliance.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Shoolin Pharma Chem LLP MARCS-CMS 734100 — August 18, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Reference #: 320-26-116 Product: Drugs Recipient: Recipient Name Dr. Santosh R. Patel and Mr. Rajendra C. Patel Recipient Title Managing Directors Shoolin Pharma Chem LLP 412 Deam Rise, Nr. Hetarth Park Plot, Science City Road Sola, Ahmedabad 380059 Gujarat India (b)(4) Issuing Office: Center for Drug Evaluation and Research (CDER) United States August 18, 2026 WARNING LETTER Reference number: 320-26-116 To Dr. Santosh R. Patel and Mr. Rajendra C. Patel: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice. FDA Inspection Violations were observed and documented during an inspection of your drug manufacturing facility, Shoolin Pharma Chem LLP, FEI 3038200383, at Block/Survey No. 408, B/h. Ratnamani Tubes, Nr. Maruti Inox, Indrad, Dist. Mehsana, Gujarat, India, from April 13 to 17, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. Your drug products are adulterated under section 501(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(A), in that they have been prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health. This warning letter also summarizes significant violations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your May 2, 2026, response to our Form FDA 483 in detail. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility. Insanitary Conditions Your firm manufactures APIs for domestic and foreign markets, including erectile disfunction (sildenafil citrate and tadalafil), anticonvulsant and (b)(4) agents, using nondedicated production…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Shoolin Pharma Chem LLP had FDA enforcement actions before?
- Yes. Argus HQ has recorded 6 total FDA actions tied to Shoolin Pharma Chem LLP: 1 warning letter, 5 recalls, and 0 approval records.
- What FDA violations was Shoolin Pharma Chem LLP cited for?
- The FDA Warning Letter to Shoolin Pharma Chem LLP (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Shoolin Pharma Chem LLP?
- FDA issued the letter (MARCS-CMS 734100) on 2026-08-18 and posted it publicly on fda.gov on 2026-09-01.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Shoolin Pharma Chem LLP in 2026-08-18 Warning Letter — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-shoolin-pharma-chem-llp-2026-08-18-cgmp
"FDA Cites Shoolin Pharma Chem LLP in 2026-08-18 Warning Letter — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-shoolin-pharma-chem-llp-2026-08-18-cgmp.
Argus HQ Research. "FDA Cites Shoolin Pharma Chem LLP in 2026-08-18 Warning Letter — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated." Digital Empire Holdings LLC. Accessed September 2, 2026. https://argushq.ai/fda/warning-letter/fda-wl-shoolin-pharma-chem-llp-2026-08-18-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_shoolin_pharma_chem_llp_2026_08_18_cgmp_2026,
title = {FDA Cites Shoolin Pharma Chem LLP in 2026-08-18 Warning Letter — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-shoolin-pharma-chem-llp-2026-08-18-cgmp},
note = {Accessed: September 2, 2026}
}